The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat
monkeypox in combination with standard of care (SOC). Participants will be randomly assigned
to receive oral tecovirimat plus SOC or placebo plus SOC for 14 days.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo